{
    "clinical_study": {
        "@rank": "114369", 
        "arm_group": [
            {
                "arm_group_label": "Primary Vaccination Group", 
                "arm_group_type": "Experimental", 
                "description": "Participants who never received a JE vaccine, or who received a single dose of inactivated JE vaccine, or whose JE vaccination history is unknown or not documented."
            }, 
            {
                "arm_group_label": "Booster Vaccination Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants who received at least 2 doses of inactivated JE vaccine (at least 1 year earlier for the last dose), or received a single dose of IMOJEV\u00ae, THAIJEV\u00ae, or IMOJEV\u00ae MD as part of the routine vaccination schedule (i.e., outside of Study JEC17) at least 1 year earlier"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to further characterize the safety profile of IMOJEV\u00ae.\n\n      Primary Objective:\n\n        -  To describe serious adverse events (SAEs, including adverse events of special interest\n           [AESIs]) up to 60 days after administration of one dose of IMOJEV\u00ae.\n\n      Secondary Objective:\n\n        -  To describe Grade 3 (severe) systemic Adverse Events (AEs) up to 30 minutes after\n           administration of one dose of IMOJEV\u00ae."
        }, 
        "brief_title": "Post-licensure Safety Study of IMOJEV\u00ae in Thailand", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Japanese Encephalitis", 
        "condition_browse": {
            "mesh_term": [
                "Encephalitis", 
                "Encephalitis, Japanese"
            ]
        }, 
        "detailed_description": {
            "textblock": "Participants aged 1 year to less than 5 years will be randomized to receive one injection of\n      IMOJEV\u00ae either as a primary vaccination or as a booster. Safety data will be collected for\n      60 days after IMOJEV\u00ae vaccination. The duration of each subject's participation in the trial\n      will be 60 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children requiring vaccination against Japanese encephalitis\n\n          -  Children aged 1 year to less than 5 years on the day of inclusion\n\n          -  In good general health at the time of inclusion\n\n          -  Informed consent form has been signed and dated by the parent(s)/legal guardian(s)\n\n          -  Subject and parent(s)/legal guardian(s) are able to attend the scheduled visit and\n             any additional visits that may need to be done in case of an SAE (including AESI),\n             and are able to comply with all trial procedures\n\n          -  The subject's parent(s)/legal guardian(s) have a telephone number at which they can\n             be contacted throughout the study. Exclusion Criteria:\n\n          -  Participation in another clinical trial investigating a vaccine, drug, medical\n             device, or medical procedure in the 4 weeks preceding the vaccination\n\n          -  Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned\n             receipt of any vaccine in the 4 weeks following the study vaccination\n\n          -  Planned participation in another clinical trial during the present trial period\n\n          -  Children previously vaccinated with the live attenuated Japanese encephalitis vaccine\n             CD-JEVAX\u00ae (SA14-14-2 LAV)\n\n          -  Contraindications to vaccination according to the IMOJEV\u00ae Summary of Product\n             Characteristics (SmPC)\n\n          -  Identified as a natural or adopted child of the Investigator or employee with direct\n             involvement in the proposed study\n\n          -  Children who received IMOJEV\u00ae as primary vaccination in this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "4 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "10000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981967", 
            "org_study_id": "JEC17", 
            "secondary_id": "U1111-1127-7052"
        }, 
        "intervention": [
            {
                "arm_group_label": "Primary Vaccination Group", 
                "description": "0.5 mL, Subcutaneous.", 
                "intervention_name": "IMOJEV\u00ae: Live attenuated Japanese encephalitis chimeric virus vaccine", 
                "intervention_type": "Biological", 
                "other_name": "IMOJEV\u00ae"
            }, 
            {
                "arm_group_label": "Booster Vaccination Group", 
                "description": "0.5 mL, Subcutaneous.", 
                "intervention_name": "IMOJEV\u00ae: Live attenuated Japanese encephalitis chimeric virus vaccine", 
                "intervention_type": "Biological", 
                "other_name": "IMOJEV\u00ae"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Japanese encephalitis", 
            "IMOJEV\u00ae", 
            "Japanese encephalitis chimeric virus vaccine"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "link": [
            {
                "url": "http://www.sanofipasteur.com"
            }, 
            {
                "url": "http://www.sanofi.com"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10400"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10330"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiang Mai", 
                        "country": "Thailand", 
                        "zip": "50200"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Khon Kaen", 
                        "country": "Thailand", 
                        "zip": "40002"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nakornnayok", 
                        "country": "Thailand", 
                        "zip": "26120"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nonthaburi", 
                        "country": "Thailand", 
                        "zip": "11120"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pathumthani", 
                        "country": "Thailand", 
                        "zip": "12120"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Songkla", 
                        "country": "Thailand", 
                        "zip": "90110"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "Post-licensure, Phase IV, Safety Study of IMOJEV\u00ae in Thailand", 
        "overall_contact": {
            "email": "RegistryContactUs@sanofipasteur.com", 
            "last_name": "Public Registry Sanofi Pasteur"
        }, 
        "overall_official": {
            "affiliation": "Sanofi Pasteur SA", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Thailand: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "An SAE is defined as any untoward medical occurrence that at any dose (including overdose), that: Results in death; Is life threatening; Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent or significant disability/incapacity; Is a congenital anomaly/birth defect, or Is an important medical event", 
            "measure": "Number and nature of Serious Adverse Events (including Adverse Events of Special Interests) reported following a primary or booster vaccination with IMOJEV\u00ae vaccine", 
            "safety_issue": "No", 
            "time_frame": "Day 0 up to Day 60 post vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981967"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Grade 3 AE defined as: Fever, body temperature >39.5\u00b0C for subjects aged \u2264 23 months or \u2265 39.0\u00b0C for subjects aged \u2265 2 years; for any other AEs, significant AE that prevents normal activity", 
            "measure": "Number and nature of Grade 3 systemic AEs reported after vaccination following a primary or booster vaccination with IMOJEV\u00ae vaccine", 
            "safety_issue": "No", 
            "time_frame": "30 minutes post vaccination"
        }, 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi Pasteur, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}